(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 October 2012 (26.10.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/143902 A1

(51) International Patent Classification:
C07K 14/33 (2006.01) *C07K 16/12* (2006.01)
A61K 39/08 (2006.01)

(21) International Application Number:
PCT/IB2012/051999

(22) International Filing Date:
20 April 2012 (20.04.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/478,474 22 April 2011 (22.04.2011) US
61/478,899 25 April 2011 (25.04.2011) US

(71) Applicant *(for all designated States except US)*: **WYETH LLC** [US/US]; Five Giralda Farms, Madison, NJ 07940 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SIDHU, Maninder K.** [US/US]; 35 Lowell Drive, New City, NY 10956 (US). **ANDERSON, Annaliesa Sybil** [GB/US]; 49 Hillcrest Drive, Upper Saddle River, NJ 07458 (US). **DONALD, Robert G. K.** [US/US]; 129 Kenneth Terrace, South Orange, NJ 07079 (US). **JANSEN, Kathrin Ute** [DE/US]; 57 Heather Court, Allendale, NJ 07401 (US). **KALYAN, Narender K.** [US/US]; 232 North Walnut Street, Ridgewood, NJ 07450 (US). **MININNI, Terri L.** [US/US]; 1 Pieters Court, New Windsor, NY 12553 (US). **MORAN, Justin Keith** [US/US]; 682 Sierra Vista Lane, Valley Cottage, NY 10989 (US). **RUPPEN, Mark E.** [US/US]; 6 Lea Court, Garnerville, NY 10923 (US). **FLINT, Michael James** [CA/US]; 860 Briarcliff Road NE, Apt 9, Atlanta, GA 30306 (US).

(74) Agent: **POKRAS, Bruce A.**; Pfizer Inc., Five Giralda Farms, Madison, NJ 07940 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

[Continued on next page]

(54) Title: COMPOSITIONS RELATING TO A MUTANT *CLOSTRIDIUM DIFFICILE* TOXIN AND METHODS THEREOF




FIG. 25

(57) Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant *Clostridium difficile* toxin A and/or a mutant *Clostridium difficile* toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type *C. difficile* toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

WO 2012/143902 A1

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*